Policy & Regulation
FlowMetric Life Sciences, Penn State University Launch a Collaboration Study on University and Community COVID-19 Antibody Testing
29 September 2020 - - US-based immunology testing services provider FlowMetric Life Sciences, Inc and the Huck Institutes of the Life Sciences at Penn State University have created a long-term collaboration study assessing the impact on the Centre County community's potential exposure to COVID-19 by Penn State University students returning to campus, the organisations said.

Together with Penn State's Center for Clinical Research, the Huck Institutes will collect thousands of blood samples from Penn State students and members of the Centre County community at the beginning and end of each academic semester for four academic semesters.

The samples will be sent to FlowMetric, a GLP-compliant, CLIA-certified, High Complexity clinical laboratory located in Doylestown, PA for analysis.

FlowMetric is providing validated serology testing under the FDA's Emergency Use Authorization mandate.

The test detects the presence of anti-SARS-CoV-2 (COVID-19) IgG antibodies and will identify individuals who have mounted an immune response following viral exposure, even if they are asymptomatic.

The results of the study will be reported to the PA Department of Health as part of ongoing surveillance in response to the COVID-19 pandemic.

Researchers at Penn State's Institute for Social Sciences will also be collecting questionnaire data on other impacts of COVID including economic and other health impacts.

With laboratories in Doylestown, PA (USA) and Bresso, Italy, FlowMetric Life Sciences is a globally recognized Contract Research Organization providing World-class Analytical services, Flow Cytometry and Single-Cell Proteomics capabilities, and expertise in Immunology, Cellular and Gene Therapy, Oncology, and Infectious Diseases, supporting many of the world's largest Pharmaceutical and Biotech companies.
Login
Username:

Password: